Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/22/2025 | $29.00 | Buy | Roth Capital |
| 2/20/2025 | $38.00 | Buy | B. Riley Securities |
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2025 fourth quarter ended June 30, 2025, on August 26, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q4 FY 202
Management will present Tuesday, August 12 at 12:30 pm ET Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that Company management will participate in the Canaccord Genuity 45th Annual Growth Conference, which will be held August 12-14, 2025 in Boston, MA. Electromed President and Chief Executive Officer Jim Cunniff, and Chief Financial Officer Brad Nagel will present on Tuesday, August 12 at 12:30 pm ET. Interested parties may access a live webcast of the presentation using the following link: Electromed CG Presentation. The link will also be posted on the Electromed Investor Relations website under Events
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Electromed is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products," said Jim Cunniff, Electromed's President and Chief Executive Off
Roth Capital initiated coverage of Electromed with a rating of Buy and set a new price target of $29.00
B. Riley Securities initiated coverage of Electromed with a rating of Buy and set a new price target of $38.00
SCHEDULE 13G - Electromed, Inc. (0001488917) (Subject)
SD - Electromed, Inc. (0001488917) (Filer)
10-Q - Electromed, Inc. (0001488917) (Filer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Electromed is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products," said Jim Cunniff, Electromed's President and Chief Executive Off
Key hire will drive the Company's market development and therapy adoption initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Peter Horwich as Vice President, Marketing. Mr. Horwich, an accomplished marketing veteran, brings over 20 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Horwich directed Global Strategic Marketing for Respiratory Therapies at Abiomed (now J&J MedTech), a Medical Device manufacturer of extracorporeal membrane oxygenation (ECMO) lung recovery systems, where he was responsible for global marketing
Healthcare Executive Brings More Than 30 Years of Executive Experience and Commercial Success to Electromed Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023. Mr. Cunniff will also join Electromed's Board of Directors. "We are pleased to announce the appointment of Jim Cunniff as president and CEO," said Lee Jones, Chair of the Board. "Jim is a proven executive with deep experience driving growth and profitability through excellence in products and services that benefit patients and support care teams. "As Kathle
SC 13D/A - Electromed, Inc. (0001488917) (Subject)
SC 13G/A - Electromed, Inc. (0001488917) (Subject)
SC 13G/A - Electromed, Inc. (0001488917) (Subject)
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2025 fourth quarter ended June 30, 2025, on August 26, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q4 FY 202
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2025 third quarter ended March 31, 2025, on May 13, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q3 Fiscal 2025
Company maintained strong momentum to deliver another quarter of record revenue and earnings, while continuing to invest in multiple strategic growth initiatives Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three and six months ended December 31, 2024 ("Q2 FY 2025"). Q2 FY 2025 Company Highlights Net revenue increased 18.7% to a record $16.3 million in Q2 FY 2025, from $13.7 million in the second quarter of the prior fiscal year. Operating income increased to a record $2.5 million, 15.6% of net revenues and a year-over-year increase of 12.3%. Net income was $2.0 mill